EGFR and lung cancer: Targeted therapy with tyrosine‐kinase inhibitors (TKI) including gefitinib has dramatically improved the rates of response and survival in advanced epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC).